HPR116080
Differentiated HepaRG™ Cells Cryopreserved
Liver tumor of female patient diagnosed with hepatocarcinoma and hepatitis
Sinonimo/i:
HepaRG Cell Line
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
41106514
Prodotti consigliati
product name
Differentiated HepaRG™ Cells Cryopreserved,
Origine biologica
(Liver tumor of female patient diagnosed with hepatocarcinoma and hepatitis C)
Condizioni di spedizione
dry ice
Temperatura di conservazione
−196°C
Descrizione generale
HepaRG is a human hepatoma cell line originally derived from a female patient diagnosed with hepatocarcinoma and hepatitis C. The cells possess a pseudodiploid karyotype and have been characterized as an oval ductular bipotent hepatic cell line that has the ability to differentiate into both biliary and hepatocyte lineages in the presence of DMSO. HepaRG cells are useful as an alternative to human primary cells as they retain the major functional activities of these cells. HepaRG cells express functional levels of the major xenobiotic sensors (PXR, CAR and AhR), drug transporters, phase I and II drug metabolizing enzymes as well as key hepatic transcription factors involved in stress response pathways. HepaRG cells are fully differentiated and ready to use upon receipt.
Applicazioni
See user guide for detailed protocols.
Caratteristiche e vantaggi
HepaRG cells are useful for many in vitro ADME applications, including drug metabolism,reactive metabolite formation, clearance, CYP inhibition and induction assays. They are also suitable for a variety of in vitro toxicity assays, including general hepatotoxicity, cholestasis,and viral infection. HepaRG cells have recently been grown in bioreactors, used for the generation of hepatic spheroids and been implanted into animals to produce humanized livers. The potential range of applications for HepaRG cells continues to expand at a rapid pace.
Note legali
Use of this product is subject to one or more license agreements.
HepaRG cells are patented and their use is strictly limited; consider the cells as a single use, disposable product that must be destroyed upon conclusion of a study or experiment. Propagating, reproducing, cloning, subcloning or any other use of the cells following the conclusion of a study is prohibited. Use of the cells to produce or manufacture commercial products for general sale or for use in the manufacture of products intended for general sale is prohibited. Transfer of the cells to anyone not employed within the same organization, whether for financial benefit or not, is prohibited. If you are unwilling to accept the terms of this LIMITED USE LICENSE, do not ORDER or use them, and immediately return the cells for credit. Violators of this Limited Use License will be prosecuted to the fullest extent of the law.
HepaRG cells are patented and their use is strictly limited; consider the cells as a single use, disposable product that must be destroyed upon conclusion of a study or experiment. Propagating, reproducing, cloning, subcloning or any other use of the cells following the conclusion of a study is prohibited. Use of the cells to produce or manufacture commercial products for general sale or for use in the manufacture of products intended for general sale is prohibited. Transfer of the cells to anyone not employed within the same organization, whether for financial benefit or not, is prohibited. If you are unwilling to accept the terms of this LIMITED USE LICENSE, do not ORDER or use them, and immediately return the cells for credit. Violators of this Limited Use License will be prosecuted to the fullest extent of the law.
HepaRG is a trademark of BioPredic International company
Esclusione di responsabilità
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Supplemento
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Danger
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Repr. 1A
Codice della classe di stoccaggio
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Lindsey M Ott et al.
SLAS discovery : advancing life sciences R & D, 22(5), 614-625 (2017-03-28)
Drug-induced liver injury (DILI) and drug-drug interactions (DDIs) are concerns when developing safe and efficacious compounds. We have developed an automated multiplex assay to detect hepatotoxicity (i.e., ATP depletion) and metabolism (i.e., cytochrome P450 1A [CYP1A] and cytochrome P450 3A4
Catherine C Bell et al.
Drug metabolism and disposition: the biological fate of chemicals, 45(4), 419-429 (2017-02-01)
Reliable and versatile hepatic in vitro systems for the prediction of drug pharmacokinetics and toxicity are essential constituents of preclinical safety assessment pipelines for new medicines. Here, we compared three emerging cell systems-hepatocytes derived from induced pluripotent stem cells, HepaRG
Beth Williamson et al.
Pharmacology research & perspectives, 4(5), e00264-e00264 (2016-10-08)
The nuclear pregnane X receptor (PXR) regulates the expression of genes involved in the metabolism, hepatobiliary disposition, and toxicity of drugs and endogenous compounds. PXR is a promiscuous nuclear hormone receptor (NHR) with significant ligand and DNA-binding crosstalk with the
Maxime Demazeau et al.
International journal of pharmaceutics, 524(1-2), 268-278 (2017-04-04)
In this study, we evaluated cationic liposomes prepared from diether-NH
Takafumi Tomida et al.
Journal of applied toxicology : JAT, 37(3), 382-390 (2016-08-03)
The approach for predicting the degree of drug-induced liver injury (DILI) risk was investigated quantitatively in a modified multiparametric assay using HepaRG cells. Thirty-eight drugs were classified by DILI risk into five categories based on drug labels approved by the
Articoli
Oral drug delivery involves dissolution in the small intestine and absorption across the enterocyte barrier into the portal vein followed by subsequent delivery through the liver into the systemic circulation.
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.